OverviewSuggest Edit

Numab Therapeutics is an oncology-focused biopharmaceutical company. It develops multispecific antibody-based immunotherapies. The company provides a platform that reduces the random nature of the discovery process to yield multispecific biotherapeutics for chronic inflammation and cancer.
TypePrivate
Founded2011
HQWädenswil, CH
Websitenumab.com

Latest Updates

Employees (est.) (May 2022)58(+6%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Numab

David Urech

David Urech

Chief Executive Officer, Board Member
Oliver Middendorp

Oliver Middendorp

Chief Business Officer, Board Member
Peter Lichtlen

Peter Lichtlen

Chief Medical Officer, Board Member
Sebastian Meyer

Sebastian Meyer

Chief Operating Officer
Roland Helfenstein

Roland Helfenstein

Chief Financial Officer
Daniel Snell

Daniel Snell

VP Translational Sciences
Show more

Numab Office Locations

Numab has an office in Wädenswil
Wädenswil, CH (HQ)
Einsiedlerstrasse 34
Show all (1)

Numab Financials and Metrics

Summary Metrics

Founding Date

2011

Numab total Funding

$132.3 m

Numab latest funding size

$110 m

Time since last funding

a year ago

Numab investors

Numab's latest funding round in May 2021 was reported to be $110 m. In total, Numab has raised $132.3 m
Show all financial metrics

Numab Cybersecurity Score

Cybersecurity ratingPremium dataset

A

100/100

SecurityScorecard logo

Numab Online and Social Media Presence

Embed Graph

Numab News and Updates

Novo Holdings co-leads oversubscribed CHF 100 Million (USD 110 M) Series C in Numab Therapeutics

COPENHAGEN, Denmark, May 20, 2021 /PRNewswire/ -- Novo Holdings today announced that it has co-led the oversubscribed CHF 100 million (approximately USD 110 million) Series C financing in Numab Therapeutics AG (Numab) alongside HBM Partners, with participation from new investors Forbion...

Numab Frequently Asked Questions

  • When was Numab founded?

    Numab was founded in 2011.

  • Who are Numab key executives?

    Numab's key executives are David Urech, Oliver Middendorp and Peter Lichtlen.

  • How many employees does Numab have?

    Numab has 58 employees.

  • Who are Numab competitors?

    Competitors of Numab include Calidi Biotherapeutics, Cybrexa Therapeutics and Bexion Pharmaceuticals.

  • Where is Numab headquarters?

    Numab headquarters is located at Einsiedlerstrasse 34, Wädenswil.

  • Where are Numab offices?

    Numab has an office in Wädenswil.

  • How many offices does Numab have?

    Numab has 1 office.